Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy [Medical Sciences]

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the robust responses to other receptor...

http://ift.tt/2GpW2LV